Category Archives: Uncategorised

Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

Parsippany, New Jersey and Ontario, Canada, May 15, 2023 – Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products. Under the terms of the agreement, Xediton is responsible for the registration and commercialization of these products in Canada.

Continue Reading

Losec® MUPS 20mg Tablets – NOW AVAILABLE

Xediton Pharmaceuticals Inc would like to inform you of the introduction of PrLOSEC® (Omeprazole Magnesium) Tablets, Capsules, on June 20th, 2021

Please note that the Losec® MUPS 20mg tablets have replaced the previous version of the 20mg tablets that were available as blisters of 2×15, 10×10, and bottles of 100 tables. DIN 02190915 as of June 2021

The MUPS tablet format is very similar to the current Tablet format when compared across Therapeutic classification, Actions and Clinical Pharmacology, Indications, Contraindications, Warnings, Precautions, Drug Interactions, Adverse Reactions, Dosage and Administration, Composition, Stability and Storing, Dosage Forms, Absorption and Distribution, Metabolism and Excretion, Pharmacodynamics (Human Pharmacology), Pharmacokinetics, Toxicology.

The rest of the world has substituted the Tablets format with the MUPS tablet format. Canada is one of the few countries that have not switched to the MUPS tablet yet.

There are currently two formulations of Brand Name Losec® available to patients

DIN NumberUPC CodeItem CodeProduct NameGeneric NameStrength/ Description
008465034260095684547436029Losec, 20mg CapsulesOmeprazole20mg Caps, 30s
022424624260095684257842030Losec, 20mg MUPS TabletsOmeprazole


20mg Tab, 50s